Phone: 614/488-2118
Fax: 614/488-2647

1335 Dublin Rd., Suite 124A
Columbus, OH 43215

Protocol Categories

View All Protocols

Multiple Disease Sites

Alliance A151804
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Molecular Analysis for Therapy Choice (MATCH)
ECOG EAY131 Subprotocol A
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG EAY131 Subprotocol C1
MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG EAY131 Subprotocol C2
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG EAY131 Subprotocol E
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR 790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG EAY131 Subprotocol H
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)
ECOG EAY131 Subprotocol L
MATCH Treatment Subprotocol L : Phase II Study of MLN0128(TAK-228)in Patients with Tumors with mTOR Mutations, to be incorporated into the EAY131 Master Protocol in Addendum #7
ECOG EAY131 Subprotocol V
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GITS, Renal Cell Carcinoma or Pancreatic Neuroendocine Tumor)
ECOG EAY131 Subprotocol Z1E
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG EAY131 Subprotocol Z1G
MATCH Treatment Subprotocol Z1G: Phase 2 STudy of Copanlisib in Patients with Tumors with PTEN Loss by IHC and Any PTEN Sequencing Result
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
SWOG S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors